Shield Therapeutics (LON:STX) Receives "Buy" Rating from Peel Hunt

Key Points

• Peel Hunt has reissued a "buy" rating for Shield Therapeutics, setting a price objective of GBX 15, indicating a potential upside of 82.93% from its previous close.
• Shield Therapeutics' stock opened at GBX 8.20, with a market cap of £85.42 million and a current ratio of 1.05.
• The company specializes in delivering Accrufer®/Feraccru®, aimed at addressing iron deficiency in patients, having launched the product in the U.S.

Shield Therapeutics (LON:STX - Get Free Report)'s stock had its "buy" rating reissued by research analysts at Peel Hunt in a report released on Monday,Digital Look reports. They currently have a GBX 15 price objective on the stock. Peel Hunt's price target suggests a potential upside of 82.93% from the company's previous close.

Shield Therapeutics Price Performance

Shares of LON:STX opened at GBX 8.20 on Monday. The company has a market cap of £85.42 million, a price-to-earnings ratio of -410.00 and a beta of 1.42. The business has a 50 day moving average price of GBX 5.50 and a 200 day moving average price of GBX 3.67. The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. Shield Therapeutics has a twelve month low of GBX 2.10 and a twelve month high of GBX 9.10.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.